Conclusion Taken together, these findings identified a critical link between IL-6 trans-signaling and structural alterations of peritoneal membrane and it might be a potential target for the treatment of PD patients who have developed peritoneal alterations.
Serum C-reactive protein and interleukin-6 levels are common surrogate markers used to measure inflammatory burden and predict adverse clinical outcomes in PD patients.